International Phase III clinical trial comparing a new molecule combined with rituximab with standard treatment in lymphomas
Background
An international Phase III clinical trial in lymphoma was conducted to evaluate the efficacy and tolerability of a new rituximab-based therapeutic combination compared with the reference treatment in patients with lymphoma.
The primary objective was to measure the clinical benefit in a heavily pretreated population, while ensuring the quality and comparability of data across sites.
Challenges identified
The challenges of a Phase III clinical trial in lymphoma
Pharmaspecific’s role
In this trial, Pharmaspecific’s involvement ensured a fast start-up and compliance with Good Clinical Practice (GCP). Its team also provided rigorous follow-up of data quality and harmonisation of imaging assessments across sites, contributing to the reliability of the study results.
Results
High compliance with scheduled visits and follow-up windows
Successful standardisation of imaging and clinical response data
Strict adherence to protocol timelines and requirements
Key takeaways
Explore our clinical case studies
- Oncology
- Haematology
- Virology
- Rare diseases
- Cardiology
- Medical devices
Supporting a multicentre oncology study
Setting up patient expense management and coordinating investigator sites for an international study.
- Multicentre observational study on optimising the oncology care pathway.
- Phase II clinical trial (paediatric oncology) — CINV prevention
- Phase II clinical trial in thoracic oncology in a targeted population with a rare molecular alteration
- National real-world data (RWD) centralisation project in oncology
Strengthening monitoring for an international trial
A dedicated CRA team to ensure data quality across several countries
- Multicentre Phase III trial in patients with relapsed multiple myeloma
- International Phase III clinical trial comparing a new molecule combined with rituximab with standard treatment in lymphomas.
- Bioequivalence clinical study in haematology in around twenty patients, comparing a new generic with the reference molecule
Securing the launch of a vaccine trial
Coordinated regulatory submissions in 6 countries simultaneously
Facilitating recruitment for an orphan disease
A patient concierge service to reduce the burden on a geographically dispersed population
Preparing for a regulatory inspection with confidence
An independent GCP audit to anticipate deviations before inspection
Bringing an implantable device into MDR compliance
Comprehensive regulatory support, from strategy to submission